You are here

  • Home
  • Archive
  • Volume 22, Issue Suppl 1
  • CP-105 Effectiveness and safety of protease inhibitors telaprevir and boceprevir in the treatment of hepatitis C virus infections in clinical practice

Article info

Article menu
Download PDFPDF
Clinical pharmacy
CP-105 Effectiveness and safety of protease inhibitors telaprevir and boceprevir in the treatment of hepatitis C virus infections in clinical practice

Authors

Citation

Delgado Sánchez O, Ventayol Bosch P, Lopez de las Hazas JS, et al
CP-105 Effectiveness and safety of protease inhibitors telaprevir and boceprevir in the treatment of hepatitis C virus infections in clinical practice
European Journal of Hospital Pharmacy 2015;22:A42-A43.

Publication history

  • First published March 24, 2015.
Online issue publication 
May 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions